Aggressive therapy and combination therapy in severe hyperlipidemia;Aggressive therapie und kombinationstherapie bei schweren hyperlipidamien

Wiener Medizinische Wochenschrift

Volumn 149, Issue 5-6, 1999, Pages 146-148

  Kostner, K M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Extracorporal lipid elimination; Familial hypercholesterolemia (FH); Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; COLESTIPOL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; PROBUCOL; SIMVASTATIN; TRIACYLGLYCEROL;

APHERESIS; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; DRUG EFFICACY; FAMILIAL HYPERLIPEMIA; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; REVIEW; RISK MANAGEMENT;

ANTICHOLESTEREMIC AGENTS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; CORONARY ARTERIOSCLEROSIS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PYRROLES; SIMVASTATIN;

EID: 0032954401     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. (1) Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radke M: Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 enzymes involved. Drug Metab Dispos 1997;25:321-331.
2. (2) Cham BE, Kostner K, Dwivedy AK, Colquhoun D, Shafey T, Mahon MG, Fang NX, Iannuzzi C, Smith J: Lipid apheresis: An in vivo application of plasma delipidation with organic solvents resulting in acute transient reduction of circulating plasma lipids in animals. J Clin Apheresis 1995;10:61-69.
3. (3) Cham BE, Kostner KM, Dwivedy AK, Shafey TM, Fang NX, Mahon MG, Iannuzzi C, Colquhoun DM, Smith JL: Lipid apheresis in an animal model causes in vivo changes in lipoprotein electrophoretic patterns. J Clin Apheresis 1996;11:61-70.
4. (4) Fuchs C, Windisch M, Wieland H: Selective continuous extracorporeal elimination of LDL from plasma by heparin precipitation without cations. Plasma Separation and Plasma Fractionation. 1983, pp 272-280.
5. (5) Homma Y, Mikami Y, Tamachi H, Nakaya N, Nakamura H, Goto Y: Comparison of selektivity of LDL-removal by double filtration and dextran sulfate cellulose plasmapheresis. Metabolism 1987;36: 419-425.
6. (6) Horsmans Y, Desager P, Van den Berge M, Harvengt C: Effects of Simvastatin and Pravastatin on 6 betahydroxycortisol excretion, a potential marker of cytochrome P-450 3A. Pharmacol Res 1993;28: 243-248.
7. (7) Illingworth D, Bacon S: Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous FH. Circulation 1989;79:590-596.
8. (8) Illingworth D, Bacon S: Treatment of heterozygous FH with lipid-lowering drugs. Arteriosclerosis 1989;9:121-134.
9. (9) Jacobson T, Amorosa F: Combination therapy of fluvastatin and niacin in hypercholesterolemia. Am J Cardiol 1994;73:25-29.
10. (10) Jaeger B, Meiser B, Nagel D: Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation 1997;96:154-158.
11. (11) Kostner K, Smith J, Dwivedy A, Shafey T, Fang N, Mahon M, Ianuzzi C, Colquhoun D, Cham B: Lecithin-cholesterol acyltransferase activity in normocholesterolaemic and hypercholesterolaemic roosters: modulation by lipid apheresis. Eur J Clin Invest 1997;27: 212-218.
12. (12) Lennernas H, Fager G: Pharmacodynamics and Pharmacocinetics of HMG-CoA reductase Inhibitors. Similarities and differences. Clin Pharmacogenetics 1997;32:403-425.
13. (13) Leren T, Hjermann K, Berg K: Effects of Lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygote FH patients. Atherosclerosis 1988;73:135-141.
14. (14) Lupien PJ, Moorjani S, Award J: A new approach to the management of familial hypercholesterolemia: removal of plasma cholesterol based on the principle of affinity chromatography. Lancet 1976;II: 1261-1265.
15. (15) Malloy M, Kane J, Kunitake T: Complimentarity of colestipol, niacin and lovastatin in the treatment of severe FH. Ann Int Med 1987;107:616-623.
16. (16) Stoffel W, Borberg H, Greve V: Application of specific extracorporeal removal of LDL in FH. Lancet 1981;II:1005-1007.
17. (17) The Pravastatin Multicenter Study Group II: Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med 1993;153:1321-1329.
18. (18) Thompson GR, Lowenthal R, Myant MB: Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet 1975;1:1208-1211.
19. (19) Witzum J, Simmons D, Steinberg D: Intensive combination drug therapy of FH with lovastatin, probucol and colestipol. Circulation 1989;79:16-28.
20. (20) Yokohama S, Hayashi R, Satani M, Yamamoto A: Selective removal of LDL by plasmapheresis in FH. Arteriosclerosis 1985;5:613-623.